207 results on '"Carta, A. R."'
Search Results
2. Combined measure of salivary alpha-synuclein species as diagnostic biomarker for Parkinson’s disease
3. Adolescent stress differentially modifies dopamine and norepinephrine release in the medial prefrontal cortex of adult rats
4. Region-specific changes in gene expression are associated with cognitive deficits in the alpha-synuclein-induced model of Parkinson's disease: A transcriptomic profiling study
5. Nuclear ERK1/2 signaling potentiation enhances neuroprotection and cognition via Importinα1/KPNA2
6. MPTP: Advances from an Evergreen Neurotoxin
7. Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease
8. MPTP: Advances from an Evergreen Neurotoxin
9. Region-specific changes in gene expression are associated with cognitive deficits in the alpha-synuclein-induced model of Parkinson's disease: A transcriptomic profiling study
10. Genetic and Molecular Regulations of Neuronal Activity
11. Induction of Activity-Regulated Cytoskeleton-Associated Protein and c-Fos Expression in an Animal Model of Anorexia Nervosa
12. The role of glia in Parkinson's disease: Emerging concepts and therapeutic applications
13. Neuroinflammation in l-DOPA-induced dyskinesia: beyond the immune function
14. MPTP: Advances from an Evergreen Neurotoxin
15. Beneficial effects of curtailing immune susceptibility in an Alzheimer’s disease model
16. Behavioural Correlates of Dopaminergic Agonists’ Dyskinetic Potential in the 6-OHDA-Lesioned Rat
17. Adenosine A2A Receptors and Parkinson’s Disease
18. Changes in the Expression of Tonic and Phasic Neurochemical Markers of Activity in a Rat Model of L-DOPA Induced Dyskinesia
19. The Intranigral Infusion of Human-Alpha Synuclein Oligomers Induces a Cognitive Impairment in Rats Associated with Changes in Neuronal Firing and Neuroinflammation in the Anterior Cingulate Cortex
20. BDNF Alterations in Brain Areas and the Neurocircuitry Involved in the Antidepressant Effects of Ketamine in Animal Models, Suggest the Existence of a Primary Circuit of Depression
21. Different Patterns of Behavior and Gene Expression Induced by Chronic L-Dopa and A2A Antagonists Plus L-Dopa Treatments in 6- Hydroxydopamine Lesioned Rats
22. The role of microglia–lymphocyte interaction in PD neuropathology
23. Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression
24. Modulating Microglia Activity with PPAR-γ Agonists: A Promising Therapy for Parkinson’s Disease?
25. Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: Behavioural and biochemical evidence
26. Progressive Dopaminergic Degeneration in the Chronic MPTPp Mouse Model of Parkinson’s Disease
27. Dopamine and adenosine receptor interaction as basis for the treatment of Parkinsons disease
28. Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success?
29. Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders
30. The 6-Hydroxydopamine model of parkinson’s disease
31. The MPTP/Probenecid Model of Progressive Parkinson’s Disease
32. Role of Adenosine in the Basal Ganglia
33. Pathophysiological roles for purines
34. Contributors
35. Adenosine A2A Receptors and Parkinson’s Disease
36. Modeling Parkinson’s Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human α-Synuclein Oligomers
37. Metabolomics Fingerprint Induced by the Intranigral Inoculation of Exogenous Human Alpha-Synuclein Oligomers in a Rat Model of Parkinson’s Disease
38. Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19?
39. Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2WD40 Genetic Model of Parkinson’s Disease
40. Nicotine, cocaine, amphetamine, morphine, and ethanol increase norepinephrine output in the bed nucleus of stria terminalis of freely moving rats
41. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinsonʼs disease
42. Separation of haemoglobin HbE and HbA2 by the fully automated, high-pressure liquid chromatography Tosoh HLC-723 G7 analyzer
43. Long-term increase in GAD67 mRNA expression in the central amygdala of rats sensitized by drugs and stress
44. How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinsonʼs disease?
45. Potentiation of amphetamine-mediated responses in caffeine-sensitized rats involves modifications in A2A receptors and zif-268 mRNAs in striatal neurons
46. Modulatory role of adenosine A2A receptors in basal ganglia as basis for the use of A2A antagonists in the treatment of Parkinsonʼs disease: O122
47. Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment
48. Dopamine and adenosine receptor interaction as basis for the treatment of Parkinsons disease
49. Blockade of A2A receptors plus l-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from l-DOPA alone in the rat globus pallidus and substantia nigra reticulata
50. Selective modifications in GAD67 mRNA levels in striatonigral and striatopallidal pathways correlate to dopamine agonist priming in 6-hydroxydopamine-lesioned rats
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.